美国安进狄诺塞麦可以治疗骨质疏松吗？

Denosumab is a monoclonal antibody drug developed by the American company Amgen that targets the RANKL protein. The drug can competitively bind to RANKL protein with RANK protein and have an effect similar to OPG, thereby inhibiting osteoclast differentiation and activation mediated by the RANKL-RANK-OPG signaling pathway, reducing osteoclast activity, and improving bone mass and quality. At this stage, the drug is mainly used for postmenopausal patients with osteoporosis or patients who are intolerant to other drug treatments. There are also studies reporting that it is used to treat the resorption and destruction of bone structure caused by bone metastasis after breast cancer and prostate cancer.

It is worth noting that unlike bisphosphonates, which maintain their effects for a long time, denosumab does not bind to its receptors for long-term storage. There are reports that denosumab has a reversible effect on increasing bone density and improving bone turnover indicators. When drug use is interrupted (longer than the treatment interval), rapid bone loss will bring about the risk of multiple vertebral fractures.

Denosumab is easy to use and can be injected subcutaneously by the patient at 60 mg/time with an interval of 6 months. Large-scale clinical trials abroad have proven that denosumab can significantly improve bone turnover markers (BTM) in postmenopausal osteoporosis patients, including a significant reduction in the bone resorption markers C-telopeptide of type I collagen (CTX) and N-telopeptide of type I procollagen (PINP). At the same time, the bone mineral density (BMD) of the subjects' lumbar spine and hip joints was significantly increased. In its 2010 guidelines for the treatment of postmenopausal osteoporosis, the American Society of Clinical Endocrinologists listed denosumab as a first-line drug along with bisphosphonates.

Amgen Biopharmaceutical Company (Amgen) is the world's leading innovative biopharmaceutical R&D and production company. It is also one of the largest biopharmaceutical companies in the world. Its performance is no less than that of large traditional pharmaceutical companies with a century-old history. Its products have also received widespread attention once they were launched.

Recommended hot articles: /newsDetail/87465.html